Kautilya Foundation is an Management consulting firm serving the area with

Technocrats who have a keen interest in customer satisfaction. The time is right for
consulting companies to flourish. With the recent gains in the stock market, capital is
again becoming available for IT infrastructure improvements. Kautilya Foundation will
position itself to win a good deal of that emerging business. The company has been
incorporated in Ujjain and has acquired an operating permit which anticipates an enviable
cumulative net profit by the end of year two.

The Market
Central Madhya Pradesh is known as " Technocrat Belt " due to its high percentage of
technology uses. With its relatively low cost of living and ample space for
expansion, Ujjain promises to be a strong market into the foreseeable future. There are
currently over 70 companies that fit the aim of Malwa Region in the Central Madhya
Pradesh area, with only four major competitors. This combination provides a rich
opportunity, bolstered by the current up-turn in the area and national economy.

The Business Model

Kautilya Foundation will leverage the industry knowledge of its founding members to
provide outstanding service to its customers. The company will initially have as little
overhead as possible with its founders working out of their own homes, using their own
transportation means to reach clients. The company will be developed with a "customer
service and satisfaction first" mentality in an effort to build acceptance and a positive
reputation in the local industry.

The Management Team

In order for the company to be successful, Kautilya Foundation must fully leverage the
experience and insight of its management team, which includes (Sanjiv Dange, Bob
Borgware, Cary Curry, Dean Dri, and Edgar Extension). The team has over a decade of
cumulative years of experience in service operations management and information
technology support. They currently hold multiple Management industry vendor
certifications crossing several disciplines including both logical and physical network
structure and management. Over the course of their careers, the team has served in
various Management roles with Fortune 500 companies and has been successful in both
large and small environments.
1.1 Objectives

Kautilya Foundation objectives for the first five years:

1. Establish and maintain at least twenty-four full time service contract customers.
2. Establish an office in Ujjain, MP.
3. Break the Big M revenue mark.

1.2 Mission

Kautilya Foundation is an innovative business technology & Consulting company that

was founded on the belief that one company can make more than a difference, it can
change the whole face of business as we know it.

1.3 Keys to Success

• Depth of knowledge.
• Breadth of ability.
• Development of a strong business relationship with customers to gain an
understanding of their business and business needs.
• Ability to network in the industry.
Company Summary

Kautilya Foundation is incorporated in Ujjain with an operating office in Ujjain,

MP. Initial staff will consist of a small group of experienced Technocrats who's skills and
experience collectively cover a very broad segment of the open systems' distributed
client/server field. The company's initial focus will be Consulting and Marketing in
Pharmaceuticals, Management and Computer Services projects which will be developed
into ongoing support contracts.

2.1 Company Ownership

Kautilya Foundation is incorporated. The major share holders are {Adam

Authortisement, Bob Borgware, Cary Curry, Dean Dri, and Edgar Extension.)

2.2 Start-up Summary

The start-up costs for the company are detailed in the table below, and will be funded by
the founder's personal funds. There will be only small initial equipment cost as the
company will be greatly dependent upon its founders' resources. It is expected that each
employee will initially cover the cost of transportation, cell phone, and incidentals that
arise in the course of due business. The company will begin covering those costs as
revenue streams are generated. Specific guidelines and policies will be developed prior to
the sixth operating month.
Start-up

Requirements

Computer 1
Computer2
Computer3
Computer4
Computer5
Pharmaceutical Stock
Internet Connection
Building (Rent /Lease)
Pramotional Materials

Start-up Expenses
Legal 10000
Stationery etc. 3000
Voice Mail Service 2000
Website development 5000
Computers 60000
Advertising 10000
Pharmaceuticals Stocks 50000
Total Start Up Expense 1 35 000
Start-up Assets
Cash Required 45000
Other Current Assets $0
Long-term Assets $0
Total Assets 45000

Total Requirements 1 85 000

Kautilya Foundation . is a medical marketing company specializing in pharmaceutical,

biotechnical and medical detailing for the benefit of the medical community. Kautilya
Foundation Inc. is the only company of its kind; a business especially designed for
doctors and the medical community, owned and operated by Biocrats a term used for
person having knowledge in both life sciences and Management ..

The pharmaceutical market is one of the most profitable industries, with revenue in
excess of $96.3 billion annually. The problem that the pharmaceutical industry has is
simply time. Time for research and development, time for branding, time for marketing
and sales, time to gain the trust and acceptance of the medical community. In this
industry, we can equate time with money.

Two additional industries have similar situations with their products. Those industries are
the biotech and the medical device companies. While the revenues are not as great as
what one will find within the pharmaceutical industry, these companies face heavy
competition within their own individual industries.
Kautilya Foundation., has developed a method that allows all of these industries to
benefit from prelaunch marketing, product branding, and postlaunch sales support--all
accomplished with the direct intervention of practicing physicians.., gives the client
companies the opportunity to market directly to the decision makers, establishing
immediate credibility through our extensive network of physicians and other medical
professionals. Providing live conferences, 24 hours a day, seven days a week, access to a
myriad of current information on various pharmaceutical products, new biotech
developments and medical devices, medical chat rooms, and online marketing make our
e-detailing the most cost effective of any service offered.

The pharmaceutical, biotech and medical device industries will contract with DocBuzz,
Inc., to provide marketing services, and because we are practicing physicians, we have
immediate access to our colleagues. We can deliver these companies' message directly to
the decision makers for 75% of what these industries are currently budgeting. In addition,
DocBuzz, Inc., by virtue of its unique incentive program will allow additional revenue to
participating physicians and other medical practitioners.

DocBuzz has developed a winning strategy to provide the best and most up to date
information to the medical community, while providing a method for these industries to
announce, promote and market their products through respected practicing physicians.
The individual professionals within the medical community benefit by receiving the most
up to date industry information, all received via the Internet, and at the end of the e-
detailing they will have the option to request samples, additional information on the
product and/or the visit from a pharmaceutical company representative. Professionals on
our medical panel can earn points by participating in our e-detailing and/or by referral of
others who join our program.

1.1 Keys to Success

DocBuzz, Inc., has identified four key strategies that we feel are essential for success:

1. Improve access of the prescribing doctor to the pharmaceuticals via newly

developed Internet technology, to accelerate market acceptance of a product and
to increase its prescribing pattern.
2. DocBuzz, Inc., uses a grass root approach to recruit and retain participating
prescribing medical professionals through a value incentive referral point program
(VIRP). DocBuzz, Inc., as a physician owned and operated company,
understands physician's needs and offers, in addition to our unique VIRP system,
other value added programs such as CME, physician cyber meeting places and
other extensive point redemption options.
3. DocBuzz, Inc. can provide evidence-based analysis for the pharmaceutical
industry in order to justify the pharmaceutical investment in e-detailing.
4. DocBuzz, Inc., anticipates aggressive, but controlled growth, in order to maintain
the quality of our service.
 1.2 Mission

Kautilya Foundation, offers pharmaceutical, biotechnical and medical device

manufacturers a reliable, high quality alternative to in-house resources for sales and
marketing. DocBuzz, Inc., improves the return on sales and marketing investment by
accelerating the physician learning curve on prelaunch, new, and existing products--
through Web access to educational detailing and marketing research. In addition,
DocBuzz, Inc., will benefit small and innovative biotechnology and pharmaceutical
companies that do not have an extensive sales force to cover North America.

1.3 Objectives

• To establish ourselves as a premier pharmaceutical e-detailing company, targeting

medical professionals--i.e. physicians, nurse practitioners, physician assistants,
dentists, and podiatrists.
• We will offer value added services such as CME, current medical information
updates, and physician meeting facilities (chat room and bulletin board).
• To hire staff both currently identified and unidentified to implement our business
concept.
• To sign up 5% of the more than 650K prescribing medical professionals by year
three, and provide 300K pharmaceutical detailing per year, by year three.
• To reach a break-even point of $35,936 by the end of year two.

Experienced physicians founded DocBuzz, Inc., as a company providing high-level

expertise in e-detailing of pharmaceutical, biotechnical products and medical equipment
to physicians and other medical professionals. It serves to capitalize the growing number
of small and mid-sized companies as well as established larger companies to improve
upon the awareness of pharmaceutical products and to increase the written prescription
pattern of such products.

2.1 Company Ownership

DocBuzz, Inc., is a privately held Delaware corporation. Robert E. Rayder, MD, FAAP
and Michael Y. Wu, MD, FAAP, are the founders and managing partners.

2.2 Start-up Summary

Total start-up expense (including legal cost, logo design, stationery and related expenses)
comes to $99,000. The table below illustrates a complete breakdown of all start-up assets
that are needed, as total start-up requirements. Currently, we have no short-term
liabilities.

Start-up
Requirements

Start-up Expenses
Legal $3,000
Stationery etc. $20,000
Brochures $7,500
Consultants $20,000
Insurance $2,500
Rent $10,000
Research and Development $5,000
Expensed Equipment $30,000
Other $1,000
Total Start-up Expenses $99,000

Start-up Assets
Cash Required $304,000
Other Current Assets $5,000
Long-term Assets $0
Total Assets $309,000

Total Requirements $408,000

2.3 Company Locations and Facilities

DocBuzz, Inc., currently occupies a shared office space at 2476 North University Drive,
Pembroke Pines, FL 33024. The current office provides sufficient space to launch the
project; however, prior to implementation, separate facilities with easy access, and the
ability to have the T-1 or T-4 connections will be required to implement our Internet
program, which is the backbone of our business.

Services

DocBuzz, Inc., offers e-detailing of pharmaceutical products and augmentation of

pharmaceutical companies sales forces. According to the IMS Health Report,
pharmaceutical detailing is a 50 billion dollar a year industry. Detailing is the portion of
the pharmaceutical sales organization that provides information on new pharmaceutical
products, face-to-face meetings with physicians, physician assistants, and nurse
practitioners. Detailing is vital as new products are introduced, because the
pharmaceutical companies must then make the medical professionals aware of the
products, the method of administration, side effects and a myriad of other information.
DocBuzz, Inc. offers the pharmaceutical companies the ability use e-detailing, which
offers all of the benefits of the standard method of detailing, but with this difference:
DocBuzz, Inc., uses the Internet, websites, personal referral networks, conferences, and
Web conferences to achieve effective results at a lower cost to the pharmaceutical
companies.

3.1 Service Description

DocBuzz, Inc., provides physician assisted marketing and sales of pharmaceutical
products. Our service is vital during the pharmaceutical companies' introduction of new
products, the prelaunch of those products and increasing the present market share of
existing products. Our company is physician owned, therefore, we have the
understanding of the physicians' needs in the current medical environment. In addition,
physicians are more inclined to make a positive commitment when speaking to another
physician as opposed to a pharmaceutical sales representative.

DocBuzz, Inc., provides a support infrastructure to pharmaceutical companies' sales

representatives nationwide by offering 24 hour, seven day a week service through our
online literature and sampling requests.

Our company represents client companies, as an extension of its already established

pharmaceutical sales force, not as a replacement. As a physician owned company, we
understand first-hand our client's endeavor to reach the busy, hurried medical provider,
and the frustration and failure of missed contacts. We offer an additional tool to insure
that the pharmaceutical company's message is delivered and that the expenditure time
with the medical professional is more productive. The physician will not have the time to
listen to pharmaceutical sales representative but will make the time to talk to a trusted
member of the medical community. More importantly, the product recommendations are
considered more credible since the recommendation is coming from a physician. By
using our Internet sampling request, physicians will make their needs known to us, and in
turn, we pass that information directly to the sales representative. This increases the
productivity of both the sales representative and the physician.

One of the tasks of a pharmaceutical company is to provide educational descriptions of

their products to targeted physicians. This is most cost effectively achieved by the
Internet's 24/7 access availability, and our unique incentive program (VIRP). By
associating with DocBuzz, pharmaceutical representatives, a vital part of the industries
marketing and sales, could offer email response or telephone the physician at a more
convenient time 24 hours a day, seven days a week.

3.2 Sales Literature

Literature, articles, product descriptions for all of the companies products we represent,
and all of the other information that a practicing physician or other medical professional
needs to know, will be available for immediate access through our Internet site.

Introductory information about our company will also be placed on our website, but
detailed information describing our company and its positioning will be mailed to the
medical professional prior to a DocBuzz, Inc., representative telephone conference or
visit to the client's facility.

3.3 Competitive Comparison

The competition comes in several forms.

Eric Rule, a partner with Cooper & Lybrand's Integrated Healthcare Consulting Services
practice, said, "With competition intensifying in the world's pharmaceutical markets,
being the first to market is crucial to securing a product's success". In the article Survey:
Strategic issues facing the pharmaceutical industry, printed in Pharmaceutical
Representative, dated April 17, 2001, one hundred-fifty senior pharmaceutical and
biotechnology industry executives in the United States and Canada rated time-to-market
for new products and making strategic alliances successful as number one and three
respectively out of a list of twenty-three of the most important issues that face the
pharmaceutical, biotech and medical device industries. The pharmaceutical industry has
been dependant on their own in-house sales and marketing representatives to insure that
the introduction of new products is successful.

The pharmaceutical industry is using net techniques to keep the rising cost of marketing
their products to the medical community under control. Pharmaceutical companies are
actively seeking to form strategic alliances with physicians both individually and
collectively. "When industry leaders tell you that timely development of new products is
the top key issue for the fifth consecutive year, you can be sure they're pulling out all the
stops to get differentiated products to the market ahead of the competition," said Erik
Rule. Andersen Consulting produced the report How Much are Marketing and Sales
Capabilities Really Worth? What Every Pharmaceutical Executive Should Know. This
report illustrates that within the pharmaceutical market, product differentiation overall is
very small, so any differentiation must be driven through marketing and sales. The report
shows that "42% [of the difference in operating margin] is explained by marketing and
sales capabilities performance." The report continues, "There are lots of me-too products
in the market with very little differentiation. It is the job of marketing and sales to drive
the differentiation." The pharmaceutical industry is feeling the pure economic pressure of
the market place, their shareholders demand increased profits and everything the
company does costs money. The pharmaceutical companies' need to reduce sales and
marketing expense, while increasing their sales, is forcing them to try new methods,
which translates into additional competition for our company.

Andersen Consulting surveyed 68 senior marketing and sales executives representing 18

large pharmaceutical companies in North America. The finding illustrates the pressure
that the industry is experiencing. The difference between an average performance
operating margin and the high performance-operating margin is 42%. That is not much of
a difference, until one realizes that this is a one billion dollar industry, and if DocBuzz
could simply improve a companies marketing and sales capability by 30%, that would
translate into an additional $135 million in operating margin. The pharmaceutical
industry generates $93.6 billion annually.

Our greatest competition comes from the pharmaceutical industry itself. The competitive
pressure within the industry provides the perfect climate for us to launch our services.
The industry has to make marketing and strategic alliance decisions so quickly, that
markets are being ignored and these markets, when combined, are huge. For example,
currently there is no e-detailing to the thousands of Physician Assistants and Nurse
Practitioners. Research indicates that there are approximately 650,000 physicians in the
United States; however, there is at least twice that number of Physician Assistants and
Nurse Practitioners in the United States. The DocBuzz, Inc., target market, in addition to
physicians, is to the physician assistants and nurse practitioners.

DocBuzz, Inc., has identified four start-up companies that are in various stages of
development. These companies are:

• RxCentric.com;
• Busydoctor.com;
• Hankyung.com (Korea only);
• Skila.com;
• PharmaDetailing.com;
• MyDrugRep.com.

These businesses are focusing on e-detailing to the physician, but are not actively
marketing to the physician assistants or nurse practitioners. In addition, we are the only
company that is physician owned and operated. This difference is significant because as
practicing physicians, we have the ability to reach the medical decision maker. As
physicians, we have strong credibility when making a recommendation to a colleague.
This ability will translate into increased prescription pattern of pharmaceutical products
that we recommend.

3.4 Technology

DocBuzz, Inc., will have complete e-detailing facilities with the ability to prepare and
deliver interactive multimedia presentations. We will have the capabilities to provide live
chat, and prerecorded video presentations on a private and secured site.

DocBuzz, Inc., facilities house complete e-detailing operations, including the ability to
prepare and deliver customized multimedia presentations. The ability to provide this type
of interactive service is vital since it is one aspect of our company that separates us from
our competition. As technology improves, the services we offer to the pharmaceutical,
biotech and medical devices companies will grow as we incorporate the new improved
technology.

3.5 Future Services

Once we achieve adequate market share in the United States, we will expand our
operations to include South America, Japan, Israel, and Europe.

3.6 Fulfillment

DocBuzz, Inc., will provide consulting, sales and marketing service to the pharmaceutical
industry. The pharmaceutical companies will pay an upfront fee for our consulting
service. In addition, DocBuzz, Inc., will generate additional income streams by selling
products that our clients produce; retaining the difference between the wholesale and the
retail price of the product.

Additional detailed information regarding the sales forecast, unit price, sales, direct unit
cost and direct cost of sales is found in the Sales Strategy section.

Market Analysis Summary

Currently, the largest market segment is the pharmaceutical industry. In addition to

pharmaceuticals, DocBuzz, Inc., will also target the fast growing biotechnical companies
and medical device manufacturers. The market has demonstrated a sustained annual
growth of approximately 11 percent. With this growth, the R and D costs will continue to
increase. Through our prelaunch and marketing services, we will enable the
pharmaceutical products to gain faster market share and increase their return on
investment.

4.1 Market Segmentation

One of the most important marketing segments is the pharmaceutical industry, such as
Pfizer, Glaxo-Welcome and Merck. Many companies have merged, acquiring controlling
interest, forming strategic alliances, and placing others under exclusive contract and
basically controlling the majority of this industry. DocBuzz, Inc., will work with these
huge companies, but we will also work with the much smaller and lesser-known
companies that have solid financial bases, but not the ability to overcome the budget and
the in-house sales and marketing staff that the larger companies have. DocBuzz, Inc., will
provide consultation, sales and marketing, and e-detailing support to all of these
companies, regardless of size or market share.

Medical professionals comprise the key marketing component. Without this specific
target market, the pharmaceutical, biotech and medical devices industries will disappear.
All of our clients realize the importance of courting this one vital target market, the
physician. DocBuzz, Inc., has a natural advantage in courting and delivering this segment
for the benefit of all of the various markets we have targeted.

Biotech industry represents a smaller market in total revenue distributed for sales and
marketing, compared to the pharmaceutical industry; however, this industry has shown a
stable and quickly growing market.

Medical devices is the one sector that we will target that has the slowest growth.
DocBuzz, Inc., is in a natural position to assist in the development of this industry,
because we can open the doors that are closed to all but practicing members of the
medical community. Companies that offer these services are vital to the medical
community; however, until our company developed, this sector worked on the "old boy"
network. Repairs are often sent to the manufacturer. The manufacturer provides long
delays in returning the repaired equipment and it is often much more expensive than
going to the companies that we represent.

Additionally, companies that are developing and marketing new medical devices need to
have rapid entry into the market place. DocBuzz, Inc., provides this ability for the
company that is manufacturing, conducting research and development, and any other
company who needs to have immediate entry into the medical community. The marketing
of service contracts will also increase through our efforts in the future.

4.2 Target Market Segment Strategy

The building of a successful Internet e-detailing site is paramount for DocBuzz, Inc., to
provide the quantity and quality of service that will insure total success of our venture.
Each of our target markets uses the access to information that the Internet provides.
DocBuzz, Inc., provides the much needed up-to-date information to the medical
professional, then provides additional service by providing a sales and marketing
representative to work directly with them.

Each of our target markets has specific needs that are unique to their own industry.
DocBuzz, Inc., has focused on the common needs that each of these markets share. In
addition to providing the services that fill our target markets' needs, we also provide an
economic incentive for the companies to choose our company.

4.2.1 Market Trends

Escalation of cost will continue within the research and development and sales and
marketing. Each of our target markets share the same rising cost of developing a product
for the market place, and then the actual marketing of the finished product. DocBuzz,
Inc., provides for the more cost effective method of marketing finished products to the
market place. The use of e-detailing provides instant access to qualified and interested
decision makers within the medical community.

Additionally, DocBuzz, Inc. works with the company to provide market branding,
strategic marketing, prelaunch and postlaunch consulting. Our services provide speed and
access 24 hours a day, seven days a week, with the ability to download product
information immediately. DocBuzz, Inc., representatives will follow up with these busy
professionals and secure the sales that our client companies are looking for, at about 75%
of the current sales and marketing expense that the companies are currently experiencing.

4.2.2 Market Growth

According to IMS Health marketing surveys, the pharmaceutical companies are enjoying
between 10-15 percent annual growth. Additionally, the biotech industry has an annual
growth rate of approximately 14% and the medical device industry is growing at about
7% per annum. With e-detailing we can increase the growth further.

Read more:
http://www.bplans.com/medical_internet_marketing_business_plan/market_analysis_sum
mary_fc.cfm#ixzz0oASc4DTF

Strategy and Implementation Summary

The United States pharmaceutical market is the initial focus of DocBuzz, Inc.,
emphasizing the sale of pharmaceutical products to all targeted professionals. A special
DocBuzz, Inc., liaison is assigned to the pharmaceutical company to evaluate their
current market position, its strength and weaknesses. Then, DocBuzz, Inc., will design a
complimentary e-marketing strategy and a targeted list of medical professional end users.
Due to the shear amount of revenue that the pharmaceutical industry generates, this is the
primary targeted industry. The quickly growing biotech and the less quick moving
medical devices industries will receive similar service. Both of these industries require
prelaunch marketing and focusing the medical community's attention on the new
products, the benefits that these new products will bring, and basically building market
needs prior to the product's official launch.
5.1 Competitive Edge

The pharmaceutical industry is now under increase pressure to improve profitability due
to pressure from various non-pharmaceutical related entities. For example, traditionally
the pharmaceutical industry is the body that will request changes of drug labeling (what
the drug is approved for) such as prescription vs. over the counter, recently Well-Point a
California HMO set a precedent by petitioning to the FDA to change three major top
revenue generating prescription antihistamine to an over the counter status (Claritin,
Zyrtec and Allegra). DocBuzz recognizes this development and will be in a position to
assist the pharmaceutical industry to speed up through the use of prelaunch education and
marketing to increase profit.

The key to successful e-detailing is an extensive, loyal and active medical professional.
DocBuzz, Inc., is a physician owned company. This is a vital point. As practicing
physicians, we know and understand the strategy to recruit and retain physicians. We
have developed recruitment and retention tools, such as our unique VIRP, CME
programs, chat rooms, live conferences and an extensive prize gallery. As practicing
physicians, we better than anyone else, understand why a physician has certain
prescribing habits and what will encourage that physician to change those habits.

Building this type of loyal network is a new business concept and several start-up
companies are in various developmental stages that will provide similar services. These
start-up companies' strategy is to target the "top tier" pharmaceutical companies, with no
other target markets. In addition to the "top tier" pharmaceutical companies, DocBuzz,
Inc., also targets small- and medium-sized pharmaceutical, biotech and medical device
companies. As a physician owned company, we have developed a unique retention
program (VIRP) that caters to the needs of the physician.

Currently, there is no e-detailing to the thousands of ARNPs and PAs who prescribe
millions of prescriptions yearly. DocBuzz, Inc., intends to market these significant
physician extender as well. DocBuzz, Inc., plans on expanding our service to the
thousands of physicians in training (interns, residents and medical students).

5.2 Marketing Strategy

DocBuzz, Inc., marketing strategy is the core of the main strategy:

• DocBuzz, Inc., will utilize the principal's personal contacts within the
pharmaceutical, biotech and medical device industry.
• All brochures and interactive CD presentations will be designed and created by
DocBuzz, Inc.
• Personal telephone calls by one of the physicians will follow every mailing of
material.
• Live presentations and question and answer sessions will be arranged by
DocBuzz, Inc.
5.2.1 Pricing Strategy

DocBuzz, Inc., has developed a pricing strategy that provides a solid profit for our
company, while providing good value for our client companies.

• The industry average per face-to-face-detailing is $200, with poor to moderate

effectiveness.
• DocBuzz, Inc., provides e-detailing availability 24 hours a day, 7 days a week for
the modest charge of $150 per e-detailing.
• DocBuzz, Inc., offers discounts for high volume clients (package discounts).

5.2.2 Promotion Strategy

We depend on our extensive network of physicians and other professional contacts within
the medical community. As the technology and our client industries change, we will
change our strategies.

Networking and Support:

• DocBuzz, Inc., will use contacts that are known to the principals of the company
as a base on which to build our network core.
• DocBuzz, Inc., will use the Internet to deliver literature mailing requests and real
time demonstrations.
• Literature mailing, phone sales, automated multimedia Power Point presentations,
and personal visits by our principle physicians.

5.3 Sales Strategy

The specific sales strategy has been omitted due to critical internal information that is not
for public disclosure. The specific sales strategy has been omitted due to critical internal
information that is not for public disclosure. The specific sales strategy has been omitted
due to critical internal information that is not for public disclosure. The specific sales
strategy has been omitted due to critical internal information that is not for public
disclosure. The specific sales strategy has been omitted due to critical internal
information that is not for public disclosure.

5.3.1 Sales Forecast

The sales forecast monthly summary is included in the appendix. The annual sales
projections are included here in the following table.

Sales Forecast Year 1 Year 2 Year 3 Sales Pharaceutical Companies $1,775,000

$1,900,000 $3,000,000 Medical Professionals $717,000 $500,000 $1,000,000 Bio-Tech
$1,440,000 $430,000 $1,714,200 Medical Devices $600,000 $750,000 $850,000 Other
$0 $234,800 $417,992 Total Sales $4,532,000 $3,814,800 $6,982,192 Direct Cost of
Sales Year 1 Year 2 Year 3 Pharaceutical Companies $9,170 $20,000 $30,000 Medical
Professionals $2,395 $25,000 $60,000 Bio-Tech $34,200 $43,000 $55,000 Medical
Devices $24,000 $24,000 $24,000 Other $0 $0 $0 Subtotal Direct Cost of Sales

5.4 Strategic Alliances

1. Professional groups such as the AMA and other specialty organizations.

2. IMS Health (to capture individual data and physician prescription patterns).
3. PEER GROUP is currently providing marketing/consulting through non-Internet
media.
4. Technology alliance (i.e. DELL, IBM, and ATT).
5. Established Internet product distribution organizations--for example,
Amazon.com, Buy.com, and various Travel sites.
6. Other medical Internet sites for cross promotion.

5.5 Milestones

The table below indicates specific milestones that we feel are critical to our success. The
reader will notice that we listed each specific milestone, start and end date, budget
allocated (if any) the specific person responsible for the successful accomplishment. As
each milestone is reached, it is deleted out of our plan, and replaced with a new
milestone.

This is an example of why our business plan will never be complete, we view it as a
living document that is in a constant state of change and growth. We meet on a monthly
basis, to review our milestones, and meet with our strategic consultants on a monthly
basis, until such time as the consultants can be replaced with our own employees.

Milestones

Milestone Start Date End Date Budget Manager Department

Interview Plan Consultants 3/4/2001 5/1/2001 $0 Mike Wu Admin
Write Business Plan 5/3/2001 6/3/2001 $1,500 DFN Consultant
Presign Pharma companies 5/20/2001 7/5/2001 $600 Mike Wu Admin
Call Center Alliance 5/1/5393 7/5/2001 $0 DFN Consultant
Global-Outsource Call Center 7/5/2001 12/30/2001 $3,000 Christian Rose G-O President
Other 5/1/2001 12/30/2001 $0 Dr. Rayner Admin
Totals $5,100

Read more:
http://www.bplans.com/medical_internet_marketing_business_plan/strategy_and_implem
entation_summary_fc.cfm#ixzz0oATOQJ42
Management Summary

The company recognizes that initially we have management gaps. The company is
seeking to fill these positions, and should the company require the services of one or
more of these positions, the company will hire a consultant to fill the role of a virtual
executive as the immediate need presents itself.

Robert E. Rayder, MD, FAAP Founder and Principal

Michael Y. Wu, MD, FAAP Founder and Principal

Dr's. Rayder and Wu are university-trained pediatricians with a combined 35 years

experience in successful private practice. They have significant involvement in the
medical and pharmaceutical communities. Both hold faculty positions in several
university/medical schools.

CEO (TBA): We are actively searching a dynamic individual MBA with both
pharmaceutical and Internet expertise to manage the overall operation of the company.

IT Director (TBA): The IT director will oversee the IT development of the company
including Web development.

CFO (TBA): The CFO will be in charge of the overall finance of the company.

Marketing Director (TBA): The marketing director will develop and implement the
marketing plan of the company.

Financial Plan

We are looking to fund a total package of $836,000 to support our growth plan,
management style and vision. This total package has been broken into three phases,
which is important to note, since at any time the management may decide that further
funding is not necessary.

Our three-year sales projection shown below, profit and loss statement, cash flow
analysis and balance sheet herein supports this financial plan.

7.1 Important Assumptions

The table below summarizes key financial assumptions.

General Assumptions
Year 1 Year 2 Year 3
Plan Month 1 2 3
Current Interest Rate 10.00% 10.00% 10.00%
Long-term Interest Rate 10.00% 10.00% 10.00%
Tax Rate 30.00% 30.00% 30.00%
Other 0 0 0

7.2 Key Financial Indicators

The following benchmark chart indicates our key financial indicators for the first three
years. We project major growth in sales and operating expenses during times of
expansion.

7.3 Break-even Analysis

The table below summarizes the break-even analysis. The break-even analysis has been
calculated on the "burn rate" of the company. The company feels that this gives the
investor a more accurate picture of the actual risk of the venture.
Break-even Analysis

Monthly Revenue Break-even 55,836

Assumptions:
Average Percent Variable Cost 2%
Estimated Monthly Fixed Cost 54,976

7.4 Projected Profit and Loss

The table and charts below summarize the profit and loss for the first three fiscal years.
Pro Forma Profit and Loss
Year 1 Year 2 Year 3
Sales Rs4,532,000 $3,814,800 $6,982,192
Direct Cost of Sales $69,765 $112,000 $169,000
Other Production Expenses $0 $0 $0
Total Cost of Sales $69,765 $112,000 $169,000

Gross Margin $4,462,235 $3,702,800 $6,813,192

Gross Margin % 98.46% 97.06% 97.58%

Expenses
Payroll $352,800 $399,100 $508,600
Sales and Marketing and Other Expenses $204,000 $214,000 $224,000
Depreciation $0 $0 $0
Leased Equipment $30,000 $30,000 $30,000
Utilities $0 $0 $0
Insurance $0 $0 $0
Rent $19,992 $20,000 $20,000
Payroll Taxes $52,920 $59,865 $76,290
Other $0 $0 $0

Total Operating Expenses $659,712 $722,965 $858,890

Profit Before Interest and Taxes $3,802,523 $2,979,835 $5,954,302

EBITDA $3,802,523 $2,979,835 $5,954,302
Interest Expense $0 $0 $0
Taxes Incurred $1,140,757 $893,951 $1,786,291

Net Profit $2,661,766 $2,085,885 $4,168,011

Net Profit/Sales 58.73% 54.68% 59.69%

7.5 Projected Cash Flow

Cash flow projections are critical to our success. The monthly cash flow is shown in the
illustration, with one bar representing cash flow per month and the other representing the
monthly balance. The annual cash flow figures are included here on the following table.